--- title: "Hengrui Pharma falls 5% to record low" type: "News" locale: "en" url: "https://longbridge.com/en/news/306200615.md" description: "Hengrui Pharma fell 5.08% to HK$43.00. Down 17.59% over ten sessions and down 39.43% YTD." datetime: "2026-11-20T07:50:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/306200615.md) - [en](https://longbridge.com/en/news/306200615.md) - [zh-HK](https://longbridge.com/zh-HK/news/306200615.md) generator: "portal-rs" --- # Hengrui Pharma falls 5% to record low Hengrui Pharma (1276.HK) fell more than **5%** in Hong Kong trading to a record low of **HK$43.00**. The stock is down 17.59% over the past ten sessions and down 39.43% year to date. It sits 46.73% below its 52-week high of HK$80.72. The Hang Seng Index is down 5.32% over the past five sessions and down 12.68% year to date. The pharmaceuticals industry index fell 4.2% over the same period, in line with the stock's move. The company's CAR-T cancer drug Beinuoda will be included in China's basic medical insurance starting Jan. 1, 2027, with the reimbursement standard cut to 288,600 yuan from 1.29 million yuan, making it the first therapy of its kind covered by the national program. Based on public media reports. AI-generated; not investment advice. ### Related Stocks - [01276.HK](https://longbridge.com/en/quote/01276.HK.md) ## Related News & Research - [Hengrui Announces Drug Inclusions in China’s 2026 NRDL](https://longbridge.com/en/news/305570916.md) - [Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals](https://longbridge.com/en/news/303205414.md) - [USD.AI: USD.AI unlocks at least 147.12 million CHIP - Sep 2027](https://longbridge.com/en/news/306378017.md) - [CEO & Chairman Of Legion Consortium Sold 32% Of Their Shares](https://longbridge.com/en/news/306378655.md) - [Lean and Mathlib Communities Verify Levent Alpöge’s Riemann Hypothesis Proof](https://longbridge.com/en/news/306379574.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**